After yet another FDA delay regarding Vascepa's NCE status, Amarin (AMRN +3.21%) investors may have something to celebrate today: The company stayed true to its reported timeline and has launched its lipid-lowering drug. While this launch does signify progress at the company, it will go head to head with Lovaza, a drug marketed by pharma giant GlaxoSmithKline (GSK +0.24%). In this video, our health care analyst Max Macaluso discusses whether this is news investors should welcome -- and what they should be wary of.
